Physicians' Academy for Cardiovascular Education

Older adults should also be treated to lower LDL-c

5' education - Jan. 18, 2021 - Prof. Børge Nordestgaard, MD

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD
5 Things a cardiologist needs to know about GLP-1 RA

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD

Clinical outcome trial with IV iron in patients with iron deficiency, stabilized after acute HF

3' education - Dec. 15, 2020 - Prof. Peter van der Meer, MD, PhD
5 Things a cardiologist needs to know about GLP-1 RA

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD
5 Things a cardiologist needs to know about GLP-1RA

Role of GLP-1RA in practice

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD
5 Things a cardiologist needs to know about GLP-1RA

How do GLP-1RAs work?

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD

Update on COVID-19 at AHA Scientific Sessions

10' education - Nov. 24, 2020 - Anthony Fauci, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD

Strengths and limitations of one-month DAPT trial

3' education - Nov. 19, 2020 - Róisín Colleran, MD

Comparing P2Y12 inhibitors in patients undergoing elective PCI

3' education - Nov. 19, 2020 - Jur ten Berg, MD, PhD
5 Things a cardiologist needs to know about GLP-1RA

Which patients to consider for GLP-1RA?

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD

Results of omega-3 fatty acids trials may not be contradictory

3' education - Nov. 16, 2020 - Prof. Deepak Bhatt, MD

No effect of omega-3 carboxylic acid on MACE in high-risk patients

3' education - Nov. 16, 2020 - Prof. Michael Lincoff, MD

What is the value of a polypill with or without aspirin?

3' education - Nov. 16, 2020 - Prof. Salim Yusuf, MD

Side effects in a trial with statin, placebo and tablet-free periods

3' education - Nov. 16, 2020 - Prof. Darrel Francis, MD

Introduction: The evolving role of triglycerides

10' education - Nov. 15, 2020 - Prof. Peter LIbby, MD

No effect of omega-3 fatty acids and vitamine D supplements on incident AF

3' education - Nov. 15, 2020 - Christine Albert, MD

High incidence of thrombotic complications in hospitalized COVID-19 patients in the first and second wave

Literature - Jan. 25, 2021 - Kaptein FHJ et al., - Thrombosis Research 2020.

Risk of overall mortality in COVID-19 patients was lower in the second wave, compared with the first wave. However, cumulative incidences of thrombotic complications remained high in the second wave.

Anti-inflammatory treatment within 3 days after MI improves CV outcomes

Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

Literature - Jan. 25, 2021 - Bouabdallaoui N, et al. - Eur Heart J. 2020

A subanalysis of COLCOT showed that initiation of colchicine within the first 3 days after MI significantly reduced the risk of an ischemic CV event compared to patients on placebo.

People aged 70-100 years with elevated LDL-c are at high risk of MI and ASCVD

Literature - Jan. 21, 2021 - Mortensen MB & Nordestgaard BG., - Lancet. 2020

In a contemporary primary prevention cohort, MI and ASCVD event rates increased with higher LDL-c and older age. NNT to prevent one MI or ASCVD event was lower in people aged 70-100 years compared to younger individuals.

2021 Update to the 2017 ACC ECDP for optimization HFrEF treatment

News - Jan. 19, 2021

The ACC Expert Consensus Decision Pathway (ECDP) for optimization of HFrEF treatment provides practical guidance for physicians in managing patients with HFrEF. The 2017 ECDP has now been updated.

Patients with HF hospitalized with COVID-19 at high risk for poor outcomes

Literature - Jan. 19, 2021 - Alvarez-Garcia J, et al. - J Am Coll Cardiol. 2020

Patients with HF admitted to hospital for COVID-19 had increased risk for in-hospital mortality and needed more often ICU care and intubation and mechanical ventilation compared to patients without HF.

Endothelial injury and dysfunction in COVID-19

Literature - Jan. 19, 2021 - Evans PC et al., - Cardiovasc Res. 2020

This position paper discusses the cause and consequences of endothelial injury and dysfunction in COVID-19.

Early increase ANP after ARNI initiation associated with reverse cardiac remodeling in HFrEF

Literature - Jan. 19, 2021 - Murphy SP, et al. - JACC Heart Fail. 2020

After initiation of sacubitril/valsartan in HFrEF patients, ANP levels increased. Larger early increase in ANP was associated with improvements of measures of reverse cardiac remodeling.

Older adults should also be treated to lower LDL-c

5' education - Jan. 18, 2021 - Prof. Børge Nordestgaard, MD
Although relative risk for MI per 1 mmol/L higher LDL-c is similar across age groups, absolute risk for MI and ASCVD per LDL categories is much higher in individuals 80-100 years compared to those <70 years.

Although relative risk for MI per 1 mmol/L higher LDL-c is similar across age groups, absolute risk for MI and ASCVD per LDL categories is much higher in individuals 80-100 years compared to those <70 years.

Angiopoietin-like 3 antibody halves LDL-c levels in patients with refractory hypercholesterolemia

Literature - Jan. 18, 2021 - Rosenson RS, et al. - N Engl J Med. 2020

This phase 2 trial showed that ANGPTL3 inhibition by evinacumab significantly reduced LDL-c by ~50% at maximum dose in patients with refractory hypercholesterolemia.

An overview of the global burden of CVD and risk factors from 1990 to 2019

Literature - Jan. 14, 2021 - Roth GA, et al. - J Am Coll Cardiol. 2020

Global CVD burden has increased in almost all regions outside high-income countries. The increase was largely due to population growth and aging. In addition, attribution of risk factors like SBP, BMI, and dietary risk increased worldwide.

Lower risk of HF hospitalizations with ferric carboxymaltose in patients with iron deficiency, stabilized after acute HF

Literature - Jan. 14, 2021 - Ponikowski P, et al. - Lancet 2020

The AFFIRM-AHF trial showed that treatment with IV ferric carboxymaltose (FCM) in patients stabilized after acute HF and with concomitant iron deficiency reduced hospitalization due to HF.

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD
A study using data from the Copenhagen General Population Study showed that cholesterol in VLDL explains 50% of the increased risk from apoB-containing lipoproteins to MI, and triglycerides in VLDL explain 0%.

A study using data from the Copenhagen General Population Study showed that cholesterol in VLDL explains 50% of the increased risk from apoB-containing lipoproteins to MI, and triglycerides in VLDL explain 0%. With poll.